Australian guidelines state "Following brief surgery or procedures with short acting anaesthetic drugs, the patient may be fit to drive after a normal night's sleep. After long surgery or procedures requiring longer lasting anaesthesia, it may not be safe to drive for 24 hours or more". The increasing use of the short-acting anaesthetic drug propofol as a solitary sedative medication for simple endoscopy procedures suggests a need to review this blanket policy. Thirty patients presenting for elective day surgery were recruited as volunteers for a pre-procedure driving simulation study and randomised to propofol or placebo arms. Driving ability was assessed at baseline and then, in the propofol group, at three effect-site concentrations. Driving impairment at these concentrations of propofol was compared to that of a third group of volunteers with a blood alcohol concentration of 0.05% (g/100 ml). Driving impairment at 0.2 µg/ml propofol effect-site concentration was not statistically different to placebo. Impairment increased with propofol effect-site concentration (P=0.002) and at 0.4 µg/ml it was similar to that found with a blood alcohol concentration of 50 mg/100 ml (0.05%). Plasma propofol concentrations of 0.2 µg/ml, as might be found approximately an hour after short (<1 hour duration) propofol-only sedation for endoscopy, were not associated with driving impairment in our young cohort of volunteers.
The ability to drive a car safely is adversely affected by a range of pharmaceutical and illicit drugs. The severity and duration of impairment in driving skills after propofol-only anaesthesia remains unclear. Currently, Australian guidelines require patients to refrain from driving a motor vehicle until at least the next day after any sedation or general anaesthetic. Sethi et al performed a meta-analysis of nine studies assessing the safety and recovery time after deep propofol-only sedation in comparison to other traditional sedative agents (midazolam and/or opioid) for upper and lower gastrointestinal endoscopic procedures. They found that propofol-only sedation was associated with better sedation and shorter recovery times without an increase in cardiopulmonary side-effects. Given this shorter recovery period and increasing use of propofol-only sedation during day surgeries, it would be useful to assess impairment and recovery times of complex psychomotor functions such as driving a motor vehicle.
Three clinical trials have examined the psychomotor recovery and driving skills of patients undergoing routine upper or lower gastrointestinal endoscopy before and after propofol-only sedation. All have found no significant impairment at one or two hours postoperatively. A number of studies have examined the effect of blood alcohol concentrations upon psychomotor performance and driving ability. It is often used as a benchmark comparator when assessing psychomotor and driving impairment by other drugs 15, 19, 22, [24] [25] [26] [27] and the World Health Organization (WHO) has previously recommended that behavioural effects of drugs be compared to those of alcohol.
The use of driving simulation as a measure of real-life driving performance has been validated in a wide body of research examining the effects of pharmaceutical drugs, psychoactive agents and other psychomotor modulators.
This research aimed to determine a plasma propofol concentration that does not cause significant driving impairment and to estimate the time after short propofolonly sedation at which patients are likely safe to drive. Driving impairment with the maximum legal blood alcohol concentration was used as a comparator to qualify impairment.
Materials and methods
The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTN: 12611000385943). Ethics approval was granted by the Human Ethics Research Committee at Monash Health with acceptance by Monash University through the Mutual acceptance program (Project No. 11130A). After obtaining consent, 30 patients presenting for elective day surgery volunteered for the study that was conducted in the immediate preoperative period. They were randomised to either a placebo (saline) or propofol group by sealed envelopes in a one-to-two ratio. We excluded volunteers with illnesses or injuries that would impair their ability to drive, with allergies to propofol or vial constituents and those with conditions that would interfere with propofol pharmacokinetics.
The data for the alcohol group were collected separately at Swinburne University Centre for Human Psychopharmacology with ethics approval from the Human Ethics Research Committee at Swinburne University (HREC No: 04/10 Evaluation and amelioration of the short-term physiological and cognitive after-effects of alcohol intoxication). Eighteen healthy volunteers completed that trial. They reported no past or present alcohol or drug abuse problems, as defined by DSM IV, 1994. Participants were required to be moderate drinkers (0.5-1 drink per day for females and 1-3 drinks per day for males), with body mass index below 28. In all three groups participants had a valid full driver's licence (no probationary or learner drivers) to ensure that they had at least three years of driving experience.
The driving simulator used was the CyberCAR ™ LITE driver training evaluation simulator. The steering wheel, a 'Force Feedback' with integrated horn, indicators, headlights, ignition, automatic gears and handbrake, was affixed to a bench. The brake and accelerator pedals were placed underneath the bench and held in place with a non-slip mat. Participants could adjust the pedal and seat position to suit their height. The simulator task was projected onto a 175 cm x 120 cm white screen (distance from steering wheel was 280 cm). Participants observed a two-dimensional computer-generated driving scene, as they would through a vehicle windscreen. The simulated dashboard, which was also projected onto the white screen, included a speedometer, rear-view mirror and side mirrors. The tasks employed a simulated conventional motor vehicle with automatic transmission. The driving simulator program consisted of two modules: 'Basic Driving Module' and the 'Driving Module'. The Basic Driving Module was administered for training, to familiarise participants with the driving simulator and to ensure that they felt confident with the steering, accelerator and brake pedal. The Driving Module consisted of two tasks-'freeway traffic conditions' and 'city traffic conditions'. Each task took approximately five minutes to complete. The program recorded each driver's performance continuously on a range of variables, in terms of vehicle management and conformance to the pre-programmed set of driver and vehicle standard operating procedures. For the current study a subset of 33 relevant variables was analysed, where each reflected an error that can occur during the driving tasks. In accordance with the CyberCAR LITE driving simulator manual, each variable score was multiplied by that variable's 'loading factor', a number which represents the severity of the error, and subsequently all adjusted variable scores were summed to give an overall vehicle control error and signalling error score. Lower scores indicate better driving performance.
All groups of volunteers were first oriented to the driving simulator. In the propofol and placebo groups, an intravenous cannula was inserted into the subject's non-dominant arm and connected via minimum volume tubing to a targetcontrolled infusion (TCI) pump. To reduce measurement error due to practise effects, subjects underwent five training and practise modules. Baseline driving ability was recorded with subjects completing the two city and freeway simulations prior to administration of propofol, placebo or alcohol.
After baseline measurements were completed, propofol or placebo was administered via an Alaris® PK syringe pump. The Schnider model , was chosen over the Marsh model due to more accurate effect-site targeting. Effect-site concentrations were initially set at 0.2 µg/ml and the subjects repeated both driving scenarios. The testing was further repeated on each volunteer at concentrations of 0.4 and 0.6 µg/ml. Due to time constraints in the pre-theatre environment and the benefit of effect-site targeting, the original methods stated in the clinical trial registration to target six plasma levels was replaced with three effect-site concentrations. These concentrations were chosen due to previous evidence of significant psychomotor impairment at plasma concentrations of 0.8 µg/ml and the effect-site EC 05 and EC 50 of propofol for loss of consciousness being respectively 1.5 µg/ml and 2.8 µg/ml. These low concentrations allowed simulation with effect-site concentrations that were unlikely to cause loss of consciousness in volunteers, and which might be found in the minutes to hours immediately after short-term propofol-only sedation.
In the alcohol group, after simulator orientation and baseline testing, alcohol was administered according to a weight-related dose. The participants consumed 1.3 grams of alcohol per kilogram of body weight over a three-hour period (an average of 6-8 standard alcoholic drinks). Throughout the three-hour drinking period, each participant's blood alcohol concentration (BAC) was monitored by breathalyser until BAC reached 0.1% (g/100 ml). Once the target BAC was reached, each volunteer completed the same series of driving simulations as the propofol and placebo groups. This was repeated when the BAC fell again to 0.05%.
Statistical analysis
Differences in baseline total driving scores and demographics of all three groups were analysed using oneway analysis of variance (ANOVA) or Student's t-test where appropriate. Variables were divided into two major groupsvehicle control and signalling error scores. Within the propofol and placebo groups repeated measures ANOVA was used to analyse vehicle control scores, signalling error scores and individual variables between the four measurement times (baseline and the three effect-site concentrations). Pairwise comparisons of means were adjusted using the Bonferroni correction as appropriate. Partial eta-squared was used to report effect size , .
To analyse differences in driving performance between the propofol and placebo groups at each of the three effect-site concentrations, total driving scores of each subject were converted to reflect the magnitude of change from their own baseline, henceforth termed 'driving impairment', i.e. I C = [D C -D B ]/D B ; where I C = Driving impairment at concentration C, D C = Total driving score at concentration C and D B = total driving score at baseline.
Unpaired t-tests were employed to analyse differences between driving impairment in the propofol group versus placebo group at each effect-site concentration. Statistical analysis was performed with IBM SPSS 19.0.
Comparison of propofol data to alcohol data was conducted by calculation of mean driving impairment at a BAC of 0.05% and plotting this against a non-linear regression model of mean driving impairment at increasing effect-site concentrations of propofol (GraphPad Prism 6.0). The point at which the regression model intersected with the impairment seen with 0.05% BAC was determined.
Results
The demographic data for all subjects are shown in Table 1 . Two volunteers in the propofol group and one in the placebo group could not finish the simulations and were not included in the analysis. One participant in the propofol group had to stop due to pain caused by the propofol infusion, the other two due to unexpected changes in the order of the surgical list.
There were no significant differences in vehicle control error scores between the different placebo measurements, P=0. 16 . In the propofol group, vehicle control error scores differed significantly between the baseline and the three effect-site concentrations, P=0.002 (Table 2) . Pairwise comparisons of means in the propofol group demonstrated significant differences in vehicle control error scores at the 0.6 µg/ml concentration compared to all other levels ( Table 3 ).
There were no significant differences in signalling error scores among the different placebo concentrations, P=0.74. In the propofol group total signalling errors differed significantly across the baseline and three effect-site concentrations, P=0.027 (Table 4) .
Pairwise comparisons of means in the propofol group found a significant increase of signalling error scores at the 0.6 µg/ml concentration compared to all other levels (Table 5 ). A series of repeated measures ANOVA were conducted to compare individual simulator variables across the baseline and three propofol effect-site concentrations. Statistically significant results are presented in Table 6 . Errors increased with increasing propofol concentration in all cases.
A summary of overall driving impairment scores in all groups is shown in Table 7 .
Non-linear regression was performed on driving impairment data and a line of best fit for driving impairment due to propofol effect-site concentration is shown in Figure 2 . The driving impairment of the alcohol group with a BAC of 0.05% is 23.3%. Graphically this degree of impairment in driving ability correlates with a propofol concentration of 0.38 µg/ml.
Discussion
The present study observed that at a propofol effectsite concentration of 0.2 µg/ml there were no statistically significant decrements in driving performance compared to a zero propofol concentration. Driving impairment, consistent with impairment observed with a BAC of 0.05%, was apparent at an effect-site concentration of approximately 0.4 µg/ml. Together with existing research in this area, these results suggest that patients undergoing propofol-only sedation may be capable of driving a car safely sooner than the current Australian guidelines suggest. This study demonstrated lane wandering (deviation from the centre of the lane) to be the most sensitive to driving impairment, consistent with previous studies on impairment by drugs including alcohol 10, 11, [17] [18] [19] [20] 26, 42, 43 . The impairment in similar components of driving ability secondary to alcohol and propofol may be due to the common effects of the drugs on gamma-aminobutyric acid A (GABA A ) receptors 44, 45 . Pribram et al described three domains of attention and cognition involved in the processing of, and response to, stimuli, these being arousal (phasic physiological responses to novel stimuli), activation (tonic physiological readiness to respond), and effort (voluntarily exerted coordination exerted between arousal and activation). The domains are driven by noradrenergic, dopaminergic and cholinergic neurotransmission respectively. GABA has an inhibitory effect on all of these systems, thus producing the sedative effects of these drugs and similar profiles of impairment in driving. This is in comparison to illicit substances such as amphetamines which appear to have their detrimental effects on driving ability by causing perceptual narrowing or tunnel vision.
While there were no statistically significant differences in Table 7 Comparison of mean driving impairment between propofol and placebo groups at all effect-site concentrations the placebo group across the multiple testing timepoints, participants did demonstrate an initial trend of improvement from baseline in the second and third tests (equivalent measurement points to 0.2 µg/ml and 0.4 µg/ml) and then an increase in impairment (return to baseline) in the final test (equivalent to 0.6 µg/ml). A simple practise effect would not explain these results that may be due to interplay between improving performance due to practise effects and a gradual decrease in performance due to fatigue, loss of motivation and concentration-'fatigue effects'. At 0.2 µg/ml, there was a non-significant 8% mean increase in total driving errors (<1 absolute error). Similar blood propofol concentrations were associated with a lack of driving impairment (assessed by a driving simulator) in two trials by Horiuchi et al 9, 10 . In one study they found no driving impairment and blood propofol concentrations of ≤0.1 µg/ml at 60 minutes after endoscopy when a single bolus of propofol was administered for sedation but ongoing impairment at 120 minutes when midazolam was the sedating agent. A control group who received no anaesthetic for their endoscopy did not have any driving impairment or improvement following endoscopy. This suggests procedural factors in simple endoscopy play no significant role in driving impairment after endoscopy and practise effects in their results were also not significant. In the more recent trial, driving impairment was assessed in 48 patients, one hour after a colonoscopy with propofol-only sedation by intermittent bolus (total dose 60-300 mg), and again there was no driving impairment. They also demonstrated that blood propofol concentrations were ≤0.2 µg/ml in 94% of the patients (98% of those who received less than 200 mg of propofol). Riphaus et al also demonstrated the absence of driving impairment soon after propofol sedation. They randomised 100 patients to propofol (total dose 40-100mg) or midazolam and pethidine sedation for their endoscopy, and there was no significant driving impairment compared to baseline at two hours after the procedure in the propofol group, but there was in the midazolam and pethidine group.
When using psychomotor testing (choice reaction time and dual task tracking with secondary reaction time) to compare impairment caused by propofol and alcohol, Grant et al concluded that blood propofol levels of 0.4 µg/ml caused similar levels of impairment to a BAC of 0.05% 14, 25 , consistent with our findings.
There was a wide variation in driving ability and pharmacodynamic response to propofol within our sample population, so it would be wise to choose a lower plasma concentration as a cut-off to ensure there is a margin of safety accounting for population heterogeneity. Considering the context-sensitive half-time of propofol is 10 minutes for infusions less than one hour and the effect-site concentration 95% (EC 95 ) for loss of consciousness is 4.1 µg/ml, it would take five half-lives or 50 minutes for concentrations to drop below our safety cut-off of 0.2 µg/ml. Though contextsensitive half-times have been calculated from propofol infusions rather than intermittent boluses, several studies have shown faster recovery of psychomotor performance in patients who are sedated with an intermittent bolus technique rather than continuous infusion or TCI.
It has been demonstrated that there are sex differences in the pharmacokinetics of alcohol but when controlled for equivalent BAC there is no difference in psychomotor impairment. Potential sex differences should not then affect the validity of psychomotor impairment comparison between alcohol and propofol groups. Again there are sex differences in the pharmacokinetics of propofol but studies assessing psychomotor impairment by propofol including those assessing driving impairment have not assessed sex differences in performance impairment [9] [10] [11] 14, 58, 59 . Without data on the sex differences in psychomotor performance with propofol and because of the higher proportion of males in our study groups, the ability to generalise results from our dataset to the general public is limited.
Due to effect-site targeting having a margin of error compared to actual concentrations, the determination of actual plasma propofol concentrations post-sedation in various relevant cohorts (e.g. the elderly) would be helpful when considering whether or not our results are generalisable to other groups of patients.
Conclusion
Experimentally we have demonstrated safe driving performance (comparable to that at the legal Australian blood alcohol concentration in Australia) in a young cohort at propofol effect-site concentrations of up to approximately 0.4 µg/ml and an absence of significant driving impairment at propofol effect-site concentration of 0.2 µg/ml. The data would suggest that guidelines could be decreased to a number of hours after propofol-only sedation. Further data regarding driving impairment following propofol sedation in other populations, such as the aged, and with increased numbers, will help formulate changes in guidelines.
